Articles

Medicines for influencing the posttranslational modifications of histones – a tutorial review

Published:
2024-11-27
Authors
View
Keywords
License

Copyright (c) 2024 Miklós Bege, Anikó Borbás (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Papers in De Remediis are Open Access articles, and they are published under the terms of the Creative Commons Attribution License. Authors contributing to De Remediis retain the copyright of their article and at the same time agree to publish their articles under the terms of the Creative Commons CC-BY 4.0 License allowing third parties to copy and redistribute the material in any medium or format, and to remix, transform, and build upon the material, for any purpose, even commercially, under the condition that appropriate credit is given, that a link to the license is provided, and that it is indicated if changes were made.

Users have the right to copy, distribute and transmit an article, adapt the article and make commercial use of the article. The CC BY license permits commercial re-use of an open access article, as long as the author is properly attributed. This license permits, distribution and reproduction in any medium provided by the original work is properly cited.

The submission of a manuscript to this journal implies that, if and when the manuscript is accepted for publication by the journal, the authors agree to automatic transfer of the first publication rights to the journal, and permit the journal to apply a DOI to their articles and to archive and index them in databases. Copyrights for articles are retained by the authors.

De Remediis makes no warranties or representations as to accuracy of the materials displayed on the Site. Because of the possibility of human and mechanical error as well as other factors, De Remediis shall under no circumstances be liable for any errors or omissions. The author retains unrestricted copyrights and publishing rights.

Abstract

Epigenetic therapy is a relatively novel, but undoubtedly a promising area of pharmacology. Most epigenetic drugs act by affecting enzymes and play a role in post-translational modifications of histones. The molecular targets of these medicines include histone methyltransferases, histone demethylases, isocitrate dehydrogenases, histone acetyltransferases and histone deacetylases. Since histone modifications are important regulatory signals, abnormalities in this process often lead to tumorigenesis, therefore these medicines constitute an important class of antitumor therapy. In this tutorial review, we would like to briefly overview the medicines that affect histone modifications, focusing on the currently approved ones, and briefly mention other interesting examples.